Clinical Trial Update: Double-blind Comparative Study of TAK-875 [Phase 3]

View source ↗

Summary

Takeda reports completion of a Phase 3 double-blind comparative study of TAK-875 in diabetes mellitus. The update does not include efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• TAK-875 (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED